{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:57:05Z","timestamp":1790744225613,"version":"4.1.0"},"reference-count":54,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2026-25481253"],"award-info":[{"award-number":["RS-2026-25481253"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2026-25474868"],"award-info":[{"award-number":["RS-2026-25474868"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"award":["RS-2026-25481253"],"award-info":[{"award-number":["RS-2026-25481253"]}],"id":[{"id":"https:\/\/ror.org\/013aysd81","id-type":"ROR","asserted-by":"publisher"}]},{"award":["RS-2026-25474868"],"award-info":[{"award-number":["RS-2026-25474868"]}],"id":[{"id":"https:\/\/ror.org\/013aysd81","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011705","name":"Korea Institute of Marine Science and Technology Promotion","doi-asserted-by":"publisher","award":["RS-2025-02292973"],"award-info":[{"award-number":["RS-2025-02292973"]}],"id":[{"id":"10.13039\/501100011705","id-type":"DOI","asserted-by":"publisher"}]},{"award":["RS-2025-02292973"],"award-info":[{"award-number":["RS-2025-02292973"]}],"id":[{"id":"https:\/\/ror.org\/04cqyfy93","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>Alzheimer\u2019s disease (AD) is a neurodegenerative disorder characterized by cognitive decline and memory loss, ultimately leading to a loss of independence and reduced quality of life. As current treatments are most effective in the early stages, reliable blood-based biomarkers are required for early diagnosis, therapeutic monitoring, and disease staging. Plasma neurofilament light chain (NfL), a marker of neuroaxonal injury, is a candidate biomarker; its value relative to established amyloid- and tau-based biomarkers is unclear. A systematic review and meta-analysis comparing plasma NfL with A\u03b242, A\u03b240, the A\u03b242\/A\u03b240 ratio, and p-tau217 across cognitively normal (control, Con), mild cognitive impairment (MCI), and AD groups was conducted. Fourteen studies that met specific criteria were included. Plasma NfL and p-tau217 increased across disease stages. A\u03b242 and A\u03b242\/A\u03b240 were lower in AD\/MCI than in Con; A\u03b240 was similar across groups. Heterogeneity (I2 &lt; 99%) was observed across biomarkers. Plasma NfL reliably reflected neuroaxonal injury and disease severity from the earliest clinically detectable stage of AD. Plasma NfL may be most valuable when combined with p-tau217\/A\u03b2-based assays to provide a more comprehensive, blood-based assessment of both AD-specific pathology and neurodegeneration. Further studies are needed to validate its prognostic utility and establish clinically applicable cut-off values.<\/jats:p>","DOI":"10.3390\/ijms27198574","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T08:09:02Z","timestamp":1790323742000},"page":"8574","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Plasma Neurofilament Light Chain as a Complementary Biomarker for Alzheimer\u2019s Disease and Mild Cognitive Impairment: A Systematic Review and Meta-Analysis"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3705-6449","authenticated-orcid":false,"given":"Ka Young","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Nursing, College of Nursing, Gachon University, Incheon 21936, Republic of Korea"},{"name":"Neuroscience Research Institute, Gachon University, Incheon 21565, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki Young","family":"Shin","sequence":"additional","affiliation":[{"name":"Bio-MAX Institute, Seoul National University, Seoul 08826, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6157-6340","authenticated-orcid":false,"given":"Keun-A","family":"Chang","sequence":"additional","affiliation":[{"name":"Neuroscience Research Institute, Gachon University, Incheon 21565, Republic of Korea"},{"name":"Department of Pharmacology, College of Medicine, Gachon University, Incheon 21999, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: Toward a biological definition of Alzheimer\u2019s disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1038\/s41591-024-02988-7","article-title":"Revised criteria for the diagnosis and staging of Alzheimer\u2019s disease","volume":"30","author":"Jack","year":"2024","journal-title":"Nat. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1016\/j.neuron.2023.05.017","article-title":"Blood-based biomarkers for Alzheimer\u2019s disease: Current state and future use in a transformed global healthcare landscape","volume":"111","author":"Hampel","year":"2023","journal-title":"Neuron"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"8216","DOI":"10.1002\/alz.14184","article-title":"Recommendations for clinical implementation of blood-based biomarkers for Alzheimer\u2019s disease","volume":"20","author":"Mielke","year":"2024","journal-title":"Alzheimers Dement."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S1474-4422(21)00361-6","article-title":"Blood-based biomarkers for Alzheimer\u2019s disease: Towards clinical implementation","volume":"21","author":"Teunissen","year":"2022","journal-title":"Lancet Neurol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/jama.2020.12134","article-title":"Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders","volume":"324","author":"Palmqvist","year":"2020","journal-title":"JAMA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","article-title":"Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology","volume":"81","author":"Ashton","year":"2024","journal-title":"JAMA Neurol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1002\/alz.13542","article-title":"Plasma Abeta42\/Abeta40 and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer\u2019s disease","volume":"20","author":"Rissman","year":"2024","journal-title":"Alzheimers Dement."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"208","DOI":"10.5582\/ddt.2025.01055","article-title":"The pTau217\/Abeta(1-42) plasma ratio: The first FDA-cleared blood biomarker test for diagnosis of Alzheimer\u2019s disease","volume":"19","author":"Hu","year":"2025","journal-title":"Drug Discov. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1097\/MS9.0000000000004609","article-title":"FDA approval of the Lumipulse G PTau217\/beta-amyloid 1-42 plasma ratio test: A new era in accessible Alzheimer\u2019s diagnosis","volume":"88","author":"Ayalew","year":"2026","journal-title":"Ann. Med. Surg."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e71644","DOI":"10.1002\/alz.71644","article-title":"Multicenter validation of plasma p-tau217\/amyloid beta 1-42 ratio in symptomatic Alzheimer\u2019s disease","volume":"22","author":"Moghekar","year":"2026","journal-title":"Alzheimers Dement."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","article-title":"Neurofilaments as biomarkers in neurological disorders","volume":"14","author":"Khalil","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41591-018-0304-3","article-title":"Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer\u2019s disease","volume":"25","author":"Preische","year":"2019","journal-title":"Nat. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1038\/s41467-021-23620-z","article-title":"A multicentre validation study of the diagnostic value of plasma neurofilament light","volume":"12","author":"Ashton","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_15","first-page":"n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ (Clin. Res. ed.)"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3343\/alm.2024.0498","article-title":"Diagnostic Performance of Eight Blood-based Biomarkers in a Well-characterized Korean Cohort of Preclinical Alzheimer\u2019s Disease","volume":"45","author":"Chae","year":"2025","journal-title":"Ann. Lab. Med."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Lu, Y., Cui, L., Huang, L., Xie, F., and Guo, Q.H. (2025). Predicting amyloid status in mild cognitive impairment: The role of semantic intrusions combined with plasma biomarkers. Front. Aging Neurosci., 17.","DOI":"10.3389\/fnagi.2025.1624513"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1093\/brain\/awab163","article-title":"Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects","volume":"144","author":"Pereira","year":"2021","journal-title":"Brain"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Wang, Y., Cui, L., Pan, F.F., Zhang, Z., Huang, L., Miao, Y., Guan, Y.H., and Guo, Q.H. (2025). Validation of the robustness of blood-based biomarkers for predicting amyloid-\u03b2 positivity in Chinese populations. Front. Aging Neurosci., 17.","DOI":"10.3389\/fnagi.2025.1660755"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1177\/13872877241309105","article-title":"Differences of longitudinal plasma biomarkers between single memory domain and multidomain subject cognitive decline: Evidence from SILCODE","volume":"103","author":"Wei","year":"2025","journal-title":"J. Alzheimers Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1001\/archneur.57.1.100","article-title":"Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease","volume":"57","author":"Mehta","year":"2000","journal-title":"Arch. Neurol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1038\/s41467-024-46603-2","article-title":"A blood-based biomarker workflow for optimal tau-PET referral in memory clinic settings","volume":"15","author":"Brum","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e71039","DOI":"10.1002\/alz.71039","article-title":"Detecting Alzheimer\u2019s disease using digital virtual reality cognitive tests","volume":"21","author":"Fang","year":"2025","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e14526","DOI":"10.1002\/alz.14526","article-title":"Differential roles of Alzheimer\u2019s disease plasma biomarkers in stepwise biomarker-guided diagnostics","volume":"21","author":"Jang","year":"2025","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1001\/jamaneurol.2021.4654","article-title":"Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease","volume":"79","author":"Leuzy","year":"2022","journal-title":"JAMA Neurol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Wan, X., Wang, W., Liu, J., and Tong, T. (2014). Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med. Res. Methodol., 14.","DOI":"10.1186\/1471-2288-14-135"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13195-025-01692-z","article-title":"The impact of kidney function on Alzheimer\u2019s disease blood biomarkers: Implications for predicting amyloid-\u03b2 positivity","volume":"17","author":"Arslan","year":"2025","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/alz.12395","article-title":"Detecting amyloid positivity in early Alzheimer\u2019s disease using combinations of plasma A\u03b242\/A\u03b240 and p-tau","volume":"18","author":"Janelidze","year":"2022","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e258842","DOI":"10.1001\/jamanetworkopen.2025.8842","article-title":"Cerebral Amyloid Angiopathy and Downstream Alzheimer Disease Plasma Biomarkers","volume":"8","author":"Kang","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13195-025-01778-8","article-title":"Plasma biomarkers for early detection of alzheimer\u2019s disease: A cross-sectional study in a Japanese cohort","volume":"17","author":"Kubota","year":"2025","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/s13195-025-01877-6","article-title":"Speech digital biomarker combined with fluid biomarkers predict cognitive impairment through machine learning","volume":"17","author":"Wang","year":"2025","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1212\/01.WNL.0000091890.32140.8F","article-title":"Plasma A[beta]40 and A[beta]42 and Alzheimer\u2019s disease: Relation to age, mortality, and risk","volume":"61","author":"Mayeux","year":"2003","journal-title":"Neurology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"26801","DOI":"10.1038\/srep26801","article-title":"Plasma beta-amyloid in Alzheimer\u2019s disease and vascular disease","volume":"6","author":"Janelidze","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1001\/jamaneurol.2021.3180","article-title":"Head-to-Head Comparison of 8 Plasma Amyloid-beta 42\/40 Assays in Alzheimer Disease","volume":"78","author":"Janelidze","year":"2021","journal-title":"JAMA Neurol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13024-021-00451-6","article-title":"A blood-based diagnostic test incorporating plasma Abeta42\/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: Findings from a multi cohort validity analysis","volume":"16","author":"West","year":"2021","journal-title":"Mol. Neurodegener."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1001\/jamaneurol.2020.4201","article-title":"Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease","volume":"78","author":"Janelidze","year":"2021","journal-title":"JAMA Neurol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e14536","DOI":"10.1002\/alz.14536","article-title":"Plasma p-tau217 and p-tau217\/Abeta1-42 are effective biomarkers for identifying CSF- and PET imaging-diagnosed Alzheimer\u2019s disease: Insights for research and clinical practice","volume":"21","author":"Zhong","year":"2025","journal-title":"Alzheimers Dement."},{"key":"ref_38","unstructured":"U.S. Food and Drug Administration (2026, August 24). FDA Clears First Blood Test Used in Diagnosing Alzheimer\u2019s Disease, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-clears-first-blood-test-used-diagnosing-alzheimers-disease."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/s41591-021-01382-x","article-title":"Biomarkers for neurodegenerative diseases","volume":"27","author":"Hansson","year":"2021","journal-title":"Nat. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1001\/jamaneurol.2019.0765","article-title":"Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease","volume":"76","author":"Mattsson","year":"2019","journal-title":"JAMA Neurol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"85","DOI":"10.31083\/j.jin2204085","article-title":"Neurofilament Light Chain as a Potential Biomarker in Plasma for Alzheimer\u2019s Disease and Mild Cognitive Impairment: A Systematic Review and a Meta-Analysis","volume":"22","author":"Fan","year":"2023","journal-title":"J. Integr. Neurosci."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e16089","DOI":"10.1111\/ene.16089","article-title":"Plasma neurofilament light chain predicts Alzheimer\u2019s disease in patients with subjective cognitive decline and mild cognitive impairment: A cross-sectional and longitudinal study","volume":"31","author":"Mazzeo","year":"2024","journal-title":"Eur. J. Neurol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1136\/jnnp-2020-325537","article-title":"Associations of longitudinal plasma p-tau181 and NfL with tau-PET, Abeta-PET and cognition","volume":"92","author":"Rauchmann","year":"2021","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1001\/jamaneurol.2020.4986","article-title":"Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease","volume":"78","author":"Moscoso","year":"2021","journal-title":"JAMA Neurol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1002\/alz.12508","article-title":"Plasma p-tau(181) shows stronger network association to Alzheimer\u2019s disease dementia than neurofilament light and total tau","volume":"18","author":"Frank","year":"2022","journal-title":"Alzheimers Dement."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1002\/alz.12447","article-title":"Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer\u2019s disease","volume":"18","author":"Chatterjee","year":"2022","journal-title":"Alzheimers Dement."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1212\/01.wnl.0000271090.28148.24","article-title":"Mixed brain pathologies account for most dementia cases in community-dwelling older persons","volume":"69","author":"Schneider","year":"2007","journal-title":"Neurology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00401-017-1717-7","article-title":"Impact of multiple pathologies on the threshold for clinically overt dementia","volume":"134","author":"Kapasi","year":"2017","journal-title":"Acta Neuropathol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e70381","DOI":"10.1002\/alz.70381","article-title":"Plasma NfL and GFAP for predicting VCI and related brain changes in community and clinical cohorts","volume":"21","author":"Raghavan","year":"2025","journal-title":"Alzheimers Dement."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"913","DOI":"10.3233\/JAD-210342","article-title":"Plasma Neurofilament Light Chain Predicts Cognitive Progression in Prodromal and Clinical Dementia with Lewy Bodies","volume":"82","author":"Pilotto","year":"2021","journal-title":"J. Alzheimers Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e209418","DOI":"10.1212\/WNL.0000000000209418","article-title":"Association of Plasma Amyloid, P-Tau, GFAP, and NfL With CSF, Clinical, and Cognitive Features in Patients With Dementia With Lewy Bodies","volume":"102","author":"Bolsewig","year":"2024","journal-title":"Neurology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s13195-025-01848-x","article-title":"The association between plasma and MRI biomarkers in dementia with lewy bodies","volume":"17","author":"Bolsewig","year":"2025","journal-title":"Alzheimers Res. Ther."},{"key":"ref_53","first-page":"730","article-title":"The diagnostic performance of neurofilament light chain in CSF and blood for Alzheimer\u2019s disease, frontotemporal dementia, and amyotrophic lateral sclerosis: A systematic review and meta-analysis","volume":"11","author":"Forgrave","year":"2019","journal-title":"Alzheimers Dement."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1001\/jamaneurol.2019.1534","article-title":"Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis","volume":"76","author":"Bridel","year":"2019","journal-title":"JAMA Neurol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/19\/8574\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:19:21Z","timestamp":1790741961000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/19\/8574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":54,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["ijms27198574"],"URL":"https:\/\/doi.org\/10.3390\/ijms27198574","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]}}}